• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: JOHNSON & JOHNSON VISION CARE, INC. ¿ IRELAND 1-DAY ACUVUE TRUEYE (NARA A); LENSES, SOFT CONTACT, DAILY WEAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

JOHNSON & JOHNSON VISION CARE, INC. ¿ IRELAND 1-DAY ACUVUE TRUEYE (NARA A); LENSES, SOFT CONTACT, DAILY WEAR Back to Search Results
Catalog Number 1D4
Device Problem No Apparent Adverse Event (3189)
Patient Problems Corneal Ulcer (1796); Discomfort (2330)
Event Type  Injury  
Manufacturer Narrative
(b)(4).(b)(6).
 
Event Description
On 21aug2017 our affiliate in (b)(4) received an email from an eye care provider (ecp) who diagnosed a patient (pt) with a corneal ulcer while wearing the 1 day acuvue trueye brand contact lenses.A call was placed to the ecp who reported he/she wanted to change the pts power from -4.00 to -4.25.No additional medical information was provided in the call.On 21aug2017 a call was placed to the pt and additional information was provided: pt reported he/she felt a discomfort while wearing the suspect lens initially.The pt reported visits to the ecp on (b)(6) 2017, but pt could not provide the event date.The pt reported he/she was diagnosed with a corneal ulcer in the right eye; pt reports the ecp advised the pt ¿it was a side effect of wearing contact lenses¿.The pt was prescribed 3 eye drops; opieye vigamox: to use every 2 hours, ocuflox to use before bed; pt reported he/she does not wear lenses every day.Pt reported the suspect contact lens was discarded.On 31aug2017 an email was received from the pt with the medical report.Additional medical information was provided as follows: ¿marginal cornea ulcer on (b)(6) 2017; idiopathic corneal ulcer on (b)(6) 2017 ¿ pt went to 2 different hospitals.Prescription: optima drop (eye inflammation) every 2 hrs; ocuflox oint (eye inflammation) to right eye before bedtime; mungmun ocufloxacin tb (microbial infection); dexifen tb (antipyretic-analgesic); vegamox 0.5 drops (eye inflammation) every 2 hours; hyaluronic drops (dryeye) frequently; verase tb (antiinflamm-antiphlogistic); recostar tb (for peptic ulcer)¿.On 05sep2017 an email was sent to the affiliate for clarification of the 2 corneal ulcer diagnoses received: marginal cornea ulcer on (b)(6) 2017; idiopathic corneal ulcer on (b)(6) 2017.Per the affiliate, the pt reported the first treating ecp advised him/her to see a specialist.On 13sep2017 a call was placed to the pt to see if the corneal ulcer event had resolved, but no further information was received.The date of event is reported as (b)(6) 2017.No additional medical information has been received.A lot history review was performed for lot 5440740107: the batch record did not show any abnormalities in monomer and solution testing.All parameters tested were within specification.All sterilization requirements were successfully completed.Lot 5440740107 was produced under normal conditions.If additional information is received it will be reported within 30 days of receipt.Serious reportable event trends are reviewed quarterly in franchise management review meetings.
 
Manufacturer Narrative
On file review, it was noted that the (b)(6) 2017 follow-up phone call information from the pt was mistakenly omitted from the initial submission: pt reported that (b)(6) 2017 was the last visit to the ecp and pt will send the medical report; pt reported that the eye seemed to be fine; pt reported the ecp advised the pt that the corneal ulcer is healed, but the pt should not return to lens wear for about 2 months; pt reported he/she is still using the eye drops prescribed with same dosage.On (b)(6) 2017 a follow-up call was placed to the pt to check the condition of the right eye.The pt provide the additional information as follows: the pt reported he/she will be going to the eye care provider (ecp) again next week.Pt reports the treatment frequency has not changed and pt is still using the eye drops as previously reported.The pt has not yet returned to contact lens wear.The pt is currently wearing glasses.On (b)(6) 2017 a follow-up phone call was placed to the pt for additional medical information, but no additional information was received.If additional information is received it will be reported within 30 days of receipt.Serious reportable event trends are reviewed quarterly in franchise management review meetings.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
1-DAY ACUVUE TRUEYE (NARA A)
Type of Device
LENSES, SOFT CONTACT, DAILY WEAR
Manufacturer (Section D)
JOHNSON & JOHNSON VISION CARE, INC. ¿ IRELAND
one technological park plassey
limerick
EI 
Manufacturer Contact
rose harrell
7500 centurion parkway
jacksonville, FL 32256
9044433364
MDR Report Key6866328
MDR Text Key86260246
Report Number9617710-2017-05042
Device Sequence Number1
Product Code LPL
Combination Product (y/n)N
Reporter Country CodeKN
PMA/PMN Number
K073485
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,foreign,health profe
Reporter Occupation Health Professional
Type of Report Initial,Followup
Report Date 09/14/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Lay User/Patient
Device Expiration Date06/01/2021
Device Catalogue Number1D4
Device Lot Number5440740107
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/21/2017
Initial Date FDA Received09/14/2017
Supplement Dates Manufacturer Received09/14/2017
Supplement Dates FDA Received10/05/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/20/2016
Is the Device Single Use? Yes
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
-
-